Cytoplasmic Vacuolation and Tapetal Changes Induced by a Novel Analgesic Agent in Beagle Dogs.


Journal

Toxicologic pathology
ISSN: 1533-1601
Titre abrégé: Toxicol Pathol
Pays: United States
ID NLM: 7905907

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 17 4 2019
medline: 29 1 2020
entrez: 17 4 2019
Statut: ppublish

Résumé

Drug-induced unique cytoplasmic vacuolation was found in the subchronic oral toxicity study of 4-dimethylamino-1-{3-(1-methyl-1H-imidazole-2-yl)propanoyl}piperidine (DMIP), a potential therapeutic agent for neuropathic pain, in beagle dogs. In the first study, DMIP was administered at a dose of 250, 500, or 1,000 mg/kg/day once daily for 14 days. Discoloration of tapetum lucidum accompanied by tapetal swelling was observed at ≥250 mg/kg/day. The tapetal swelling was correlated to the light microscopic observation of cytoplasmic vacuolation in tapetal cells, and similar vacuolation was observed in several other tissues, including the coronary artery and aortal arch, in a dose-dependent manner. Immunohistochemistry for lysosomal-associated membrane protein 2 indicated that the vacuoles were enlarged lysosomes. However, the nature of these vacuoles was different from that of phospholipidosis because no lamellar bodies were observed. In the second study, DMIP was administered at a dose of 10, 50, or 250 mg/kg/day once daily for 14 days followed by a 14-day recovery period. Tapetal changes and systemic vacuolation were not observed at ≤50 mg/kg/day, and vacuolation observed at 250 mg/kg/day was reversible. A few reports have described the enlargement of lysosomes not attributable to phospholipid accumulation. Our findings provide further information about the toxicological implications of drug-induced lysosomal swelling.

Identifiants

pubmed: 30987541
doi: 10.1177/0192623319836678
doi:

Substances chimiques

Analgesics 0
Imidazoles 0
Lysosomal-Associated Membrane Protein 2 0
Piperidines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

494-503

Auteurs

Kei Takahashi (K)

1 Pharmaceutical Research Laboratories, Toray Industries Inc., Kamakura, Kanagawa, Japan.

Yasuhiro Morita (Y)

1 Pharmaceutical Research Laboratories, Toray Industries Inc., Kamakura, Kanagawa, Japan.

Shuji Udagawa (S)

1 Pharmaceutical Research Laboratories, Toray Industries Inc., Kamakura, Kanagawa, Japan.

Seiki Yamakawa (S)

2 Hamamatsu Branch, Gotemba Laboratory, BoZo Research Center Inc., Hamamatsu, Shizuoka, Japan.

Dai Watanabe (D)

3 Kannami Laboratory, BoZo Research Center Inc., Tagata-gun, Shizuoka, Japan.

Mayu Mutsuga (M)

1 Pharmaceutical Research Laboratories, Toray Industries Inc., Kamakura, Kanagawa, Japan.

Mayumi Nakajima (M)

1 Pharmaceutical Research Laboratories, Toray Industries Inc., Kamakura, Kanagawa, Japan.

Makoto Kohno (M)

4 Department of Bio Research, Kamakura Techno-Science Inc., Kamakura, Kanagawa, Japan.

Yohei Miyamoto (Y)

5 Clinical Research Department, Toray Industries Inc., Chuo-ku, Tokyo, Japan.

Keiyu Oshida (K)

1 Pharmaceutical Research Laboratories, Toray Industries Inc., Kamakura, Kanagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH